Vinorelbine liposomal - Taiwan Liposome Company

Drug Profile

Vinorelbine liposomal - Taiwan Liposome Company

Alternative Names: Nanoliposomal vinorelbine - Taiwan Liposomal Company; TLC-178; Vinorelbine encapsulated liposome - TLC

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Non-Hodgkin's lymphoma; Rhabdomyosarcoma

Most Recent Events

  • 11 Jul 2017 Taiwan Liposome Company has patent protection for vinorelbine liposomal in USA
  • 27 Apr 2017 Phase-I/II clinical trials in Lymphoma (Late-stage disease) in Taiwan, USA (Parenteral)
  • 27 Apr 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA, Taiwan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top